Avalo Therapeutics Expands Pipeline with Next-Gen Anti-IL-1β Antibody AVTX-010
AVTX has more than doubled off its 52-week low of $4.46.
Summary
Avalo Therapeutics is expanding its pipeline with AVTX-010, a next-generation anti-IL-1β antibody, leveraging recent clinical success and financing to target hidradenitis suppurativa and other inflammatory disorders.
Key Events · Product Development and Regulatory · AVTX
-
Pipeline Expansion with AVTX-010
Avalo announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with potential for development in hidradenitis suppurativa (HS) and other inflammatory disorders.
-
IND Submission Planned for 2027
The company expects to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027, marking an early-stage development milestone.
-
Strategic Development Leveraging Recent Success
This pipeline expansion builds on the positive Phase 2 LOTUS trial data for abdakibart (AVTX-009) and the transformational financing completed in May, demonstrating a strategic focus on the IL-1β pathway.
Analysis · AVTX · Life Sciences
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, into its pipeline. This strategic move builds on the recent positive Phase 2 results for abdakibart in hidradenitis suppurativa and the company's strong financial position, aiming to develop a potentially best-in-class treatment with extended dosing intervals. An Investigational New Drug (IND) application is planned for the first half of 2027.
At the time of this filing, AVTX was trading at $14.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $767.5M. The 52-week trading range was $4.46 to $24.27. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.